Montelukast Sodium is a leukotriene receptor antagonist indicated for asthma prophylaxis, exercise-induced bronchoconstriction and allergic rhinitis. We supply it to US manufacturers of tablets, chewable tablets and oral granules.
Data from PubChem (CID 23663996) and FDA’s substance registry
CAS number
151767-02-1
Molecular formula
C35H35ClNNaO3S
Molecular weight
608.2g/mol
FDA UNII
IUPAC name
sodium 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate
InChIKey
LBFBRXGCXUHRJY-HKHDRNBDSA-M
- Appearance
- Off-white to pale yellow, hygroscopic, optically active powder.
- Solubility
- Freely soluble in ethanol, methanol and water, and practically insoluble in acetonitrile.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Hygroscopic and sensitive to light, which converts it to the cis-isomer. Ask how it is packed and what limit the source sets for that isomer.
On the US market
- Reference product
- SingulairNDA 020829
- Approved ANDAs
- 32 with a marketed product
- Approved forms and strengths
- Chewable tablet 4 mg, 5 mg
- Tablet 10 mg
- Oral granules 4 mg per packet
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com